Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | PHASE1 | COMPLETED | 27 | — | — | Aug 4, 2020 | Apr 6, 2023 | Jun 18, 2023 | 5 | United States |
The rates of drug-related adverse events will be summarized and maximum tolerated dose will be determined.
| Arm | Type | Description |
|---|---|---|
| CDX-527 | EXPERIMENTAL | Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance. Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase. |
| Name | Type | Description |
|---|---|---|
| CDX-527 | DRUG | CDX-527 is administered by infusion every 2 weeks |
Key Inclusion Criteria: 1. Recurrent, locally advanced or metastatic solid tumor cancer excluding the following: MSI-low colorectal cancer, glioblastoma multiforme, prostate cancer, pancreatic cancer, mucosal and ocular melanoma. 2. Receipt of all standard therapies for the tumor type 3. Measurable...